Tumour lysis syndrome complicating high‐dose treatment in patients with multiple myeloma

Tumour lysis syndrome (TLS), because of its low proliferative activity, is thought to only rarely complicate the treatment of patients with multiple myeloma. However, as more aggressive therapeutic approaches are increasingly used in the management of this disease, it is conceivable that clinicians...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 1999-06, Vol.105 (4), p.938-941
Main Authors: Fassas, Athanasios B.‐T., Desikan, K. R., Siegel, David, Golper, Thomas A., Munshi, Nikhil C., Barlogie, Bart, Tricot, Guido
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Biological and medical sciences
Chemotherapy
Female
Hematology
high‐risk features
Humans
Immunoglobulin A
Immunoglobulin G
Immunoglobulin Light Chains
Kidney Diseases - chemically induced
Kidney Diseases - physiopathology
Male
Medical sciences
Middle Aged
multiple myeloma
Multiple Myeloma - complications
Multiple Myeloma - drug therapy
Pharmacology. Drug treatments
renal function
Retrospective Studies
Risk Factors
Treatment Outcome
Tumor Lysis Syndrome - etiology
tumour lysis syndrome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumour lysis syndrome (TLS), because of its low proliferative activity, is thought to only rarely complicate the treatment of patients with multiple myeloma. However, as more aggressive therapeutic approaches are increasingly used in the management of this disease, it is conceivable that clinicians will encounter this complication more frequently. A retrospective analysis of > 800 patients with multiple myeloma treated at the University of Arkansas identified nine patients who developed a marked tumour lysis syndrome following intermediate‐ or high‐dose chemotherapy. Evaluation of disease characteristics revealed association with high tumour mass, high proliferative activity, increased lactic dehydrogenase levels, plasmablastic morphology, and unfavourable cytogenetic abnormalities. Recognition of multiple myeloma patients at high risk for the development of tumour lysis syndrome and prompt intervention are required especially in the presence of abnormal baseline renal function frequently complicating the clinical course of these patients.
ISSN:0007-1048
1365-2141
DOI:10.1046/j.1365-2141.1999.01467.x